ATP13A2

Across TCGA pan-cancer cohorts, ATP13A2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATP13A2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ATP13A2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP13A2 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where ATP13A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP13A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−0.410	.017	8	view →
LUAD	Female	All	+0.321	<.001	8	view →
LSCC	All	II,III,IV	+0.284	<.001	5	view →
PDAC	All	II,III,IV	−0.406	.003	4	view →
CCRCC	All	All	+0.373	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATP13A2–HNSC

Open the HNSC breakdown →